Evolving Treatment Paradigms in Endometrial Cancer
Experts review current treatment options and emerging strategies for advanced endometrial cancer, including data from the Society of Gynecologic Oncology 2021 Virtual Annual Meeting.
Updates on Biomarker-Directed Therapy for Solid Tumors: Focus on NTRK, RET, and NRG-1
New First-Line Combination Therapies in Advanced RCC
Personalized Approaches to Treatment of Metastatic Colorectal Cancer
Transplant-Associated Thrombotic Microangiopathy
Redefining Treatment Approaches in Advanced HCC
Clinical Updates on the Treatment of Advanced Cholangiocarcinoma
Clinical Updates on Relapsed/Refractory Follicular Lymphoma: Where Are We Now and What Is Coming Next?
Expert Perspectives On Advanced Hormone Receptor-Positive Breast Cancer
The Evolving Treatment Landscape in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Multiple Myeloma Management in 2021
Refining Treatment Approaches for HER2+ Breast Cancer
The Evolving Landscape in Mantle Cell Lymphoma
Acute Myeloid Leukemia: Evolving Perspectives on Testing, Targeted Therapies, and Transplantation
Integrating Newer Therapies into Management of Adult ALL
Advanced Endometrial Cancer
Video Series Test
Hepatocellular Carcinoma: A Rapidly Evolving Treatment Landscape
Updates in Systemic Therapy for Non-Metastatic Lung Cancer
Updates in Immunotherapy for Advanced Thoracic Malignancies
Evolving Practice Patterns for Advanced Clear Cell Renal Cell Carcinoma
Triple-Negative Breast Cancer: Expert Perspectives On Recent Advances
Global Updates in Advanced Gastric Cancer from ESMO 2020
Precision Medicine: Key Updates for Treatment of NSCLC
Evolving Therapies in Chronic Lymphocytic Leukemia
Advanced Clear Cell Renal Cell Carcinoma: Putting Advances Into Practice
Acute Myeloid Leukemia: Evolving Through Targeted Therapies
Practical Implications for Treatment Strategies in Advanced Ovarian Cancer
Multiple Myeloma: Planning a Continuum of Care in 2020
Improving Outcomes in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
IDE397 Shows Early Antitumor Activity, Safety in MTAP-Deletion Urothelial Cancer and NSCLC
RVU120 Shows Early Promise in R/R Metastatic or Advanced Solid Tumors
The WEE1 Inhibitor APR-1051 Shows Early Safety and Tolerability in Advanced, Mutated Solid Tumors
TYRA-300 Is Safe, Generates Preliminary Antitumor Activity in FGFR3+ Metastatic Urothelial Cancer